10/07/2025
Combination Therapy in Migraine
Earlier this year, the Food and Drug Administration announced the approval of single-dose combination therapy with meloxicam and rizatriptan (Symbravo; Axsome Therapeutics, New York, NY]) for the acute treatment of migraine. The approval was based on clinical trial data from the MOMENTUM clinical trial (Maximizing Outcomes in Treating Acute Migraine; NCT03896009) suggesting that the absorption rate for meloxicam and rizatriptan when combined using molecular solubility enhanced inclusion complex technology is faster than for each drug by itself. For clinicians, this research highlights the importance of using multiple drug classes instead of limiting acute treatment to a single drug type.7
